Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV

AIDS Patient Care and STDs

Volumn 30, Issue 5, 2016, Pages 200-207

  Bilal, Usama ^a   Lau, Bryan ^a   Lazo, Mariana ^a,b   McCaul, Mary E ^b   Hutton, Heidi E ^b   Sulkowski, Mark S ^b   Moore, Richard D ^a,b   Chander, Geetanjali ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; COHORT ANALYSIS; DRINKING BEHAVIOR; FEMALE; FIBROSIS 4 SCORE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PROSPECTIVE STUDY; SCORING SYSTEM; VIRUS LOAD; ADVERSE EFFECTS; ALCOHOL LIVER CIRRHOSIS; ALCOHOLISM; CHRONIC HEPATITIS C; COINFECTION; COMPLICATION; HEALTH SURVEY; HEPACIVIRUS; HIV INFECTIONS; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; PROCEDURES; VIROLOGY;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COINFECTION; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 84969509083     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2016.0010     Document Type: Article

References (34)

1. Mathurin P, Bataller R. Trends in themanagement and burden of alcoholic liver disease. J Hepatol 2015;62:S38-S46.
2. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: Review and metaanalysis. J Acquir Immune Defic Syndr 2009;52:180-202.
3. Conen A, Wang Q, Glass TR, et al. Association of alcohol consumption and HIV surrogate markers in participants of the Swiss HIV cohort study. J Acquir Immune Defic Syndr 2013;64:472-478.
4. Chander G, Lau B, Moore RD. Hazardous alcohol use: A risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006;43:411-417.
5. Chander G, Josephs J, Fleishman JA, et al. Alcohol use among HIV-infected persons in care: Results of a multi-site survey. HIV Med 2008;9:196-202.
6. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: Results from the HIV Cost and Services Utilization Study. J Stud Alcohol 2002;63: 179-186.
7. Matthews GV, Neuhaus J, Bhagani S, et al. Baseline prevalence and predictors of liver fibrosis among HIVpositive individuals: A substudy of the INSIGHT Strategic Timing of Anti Retroviral Treatment (START) trial. HIV Med 2015;16:129-136.
8. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses 2010;26:511-518.
9. Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res 2005;29:1190-1197.
10. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001;34:1193-1199.
11. Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: A cohort study. Ann Inter Med 2013;158:658-666.
12. Lim JK, Tate JP, Fultz SL, et al. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis 2014;58:1449-1458.
13. Macias J, Neukam K, Mallolas J, et al. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavirboosted protease inhibitor in HIV/HCV-coinfected patients. HIV Clin Trials 2012;13:61-69.
14. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004;18:2277-2284.
15. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002;35:182-189.
16. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:S38-S41.
17. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002;16:767-774.
18. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43: 1317-1325.
19. NIAAA. Helping Patients Who Drink Too Much: A Clinician's Guide. 2005.
20. Kowalski S, Colantuoni E, Lau B, et al. Alcohol consumption and CD4 T-cell count response among persons initiating antiretroviral therapy. JAIDS 2012;61:455-461.
21. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006;20:2361-2369.
22. Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 2003;188:1192-1204.
23. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
24. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13.
25. Zha BS, Wan X, Zhang X, et al. HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes. PLoS One 2013;8:e59514.
26. Kao E, Shinohara M, Feng M, Lau MY, Ji C. Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes. Hepatology 2012;56:594-604.
27. Hinton M, Pandak W, Hylemon P, Zhou H. Cellular mechanisms by which alcohol promotes HIV protease inhibitorinduced liver lipotoxicity. FASEB J April 2015 2015;29 (Supplement):715-22.
28. McCance-Katz EF, Gruber VA, Beatty G, Lum PJ, Rainey PM. Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz. J Addict Med 2013;7:264-270.
29. Shaper AG, Wannamethee G, Walker M. Alcohol and mortality in British men: Explaining the U-shaped curve. Lancet 1988;2:1267-1273.
30. Roux P, Cohen J, Lascoux-Combe C, et al. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: The role of the physician. Drug Alcohol Depend 2011;116: 228-232.
31. Walther L, de Bejczy A, Löf E, et al. Phosphatidylethanol is superior to carbohydrate-eeficient transferrin and γ-glutamyltransferase as an alcohol marker and is a reliable estimate of alcohol consumption level. Alcoholism Clin Expl Res 2015;39:2200-2208.
32. Heo M, Leon AC. Sample sizes required to detect two-way and three-way interactions involving slope differences in mixed-effects linear models. J Biopharm Stat 2010;20: 787-802.
33. Cope R, Pickering A, Glowa T, Faulds S, Veldkamp P, Prasad R. Majority of HIV/HCV patients need to switch antiretroviral therapy to accommodate direct acting antivirals. AIDS Patient Care STDs 2015;29:379-383.
34. Marcus JL, Leyden WA, Chao CR, et al. Differences in response to antiretroviral therapy by sex and hepatitis C infection status. AIDS Patient Care STDs 2015;29:370-378.